Back to top

gene-editing: Archive

Zacks Equity Research

CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug

CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.

VRTXNegative Net Change CRSPPositive Net Change SYBXPositive Net Change DTILPositive Net Change

Zacks Equity Research

bluebird (BLUE) Stock Down 19% on Q3 Earnings & Revenue Miss

bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates. Shares decline 19% following the announcement.

BMYNegative Net Change ALKSPositive Net Change